Claims for Patent: 10,335,518

Summary for Patent: 10,335,518

Title:	Catheter locking formulation and method to prepare same
Abstract:	A method to prepare a catheter locking formulation, comprising in a first step, dissolving trimethoprim in propylene glycol at a temperature greater than room temperature, and in a final step, adding absolute ethanol at about room temperature to a solution of trimethoprim, propylene glycol, EDTA Calcium Disodium Hydrate, phosphate buffered saline, and glycerin.
Inventor(s):	Appelt; Krzysztof (Broomfield, CO), Lanzilotti; Michael (Broomfield, CO)
Assignee:
Application Number:	15/025,177
Patent Claims:	1. A method to prepare a catheter locking formulation, comprising the following steps in the following order: dissolving trimethoprim in propylene glycol at a temperature between about 50.degree. C. and about 55.degree. C. with stirring for at least 60 minutes to form a solution of trimethoprim and propylene glycol; sequentially adding at a temperature between about 50.degree. C. and about 55.degree. C., in the following order, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin, to said trimethoprim/propylene glycol solution, wherein glycerin should be added only after all solids have been completely solubilized; cooling said propylene glycol solution containing trimethoprim, propylene glycol, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin to about room temperature; adding absolute ethanol at about room temperature to a room temperature solution of trimethoprim, propylene glycol, EDTA Calcium Disodium Hydrate, phosphate buffered saline, and glycerin to form a catheter locking solution; wherein said absolute alcohol is present at a level of at least fifteen (15) weight percent of said catheter locking solution; wherein said catheter locking solution maintains shelf life stability, including no formation of precipitates, at temperatures between 0.degree. C. to about 42.degree. C. for at least three days; and wherein said catheter locking solution comprises a pH between about 8 and about 9. 2. The method of claim 1, wherein said phosphate buffered saline comprises no calcium salts or magnesium salts. 3. The method of claim 1, wherein said adding phosphate buffered saline to the propylene glycol and trimethoprim solution comprises: adding sterile water to said propylene glycol and trimethoprim solution, at a temperature between about 50.degree. C. and about 55.degree. C.; mixing, at a temperature between about 50.degree. C. and about 55.degree. C., until a trimethoprim, propylene glycol, and water solution, is completely clear and uniform; adding NaCl, KH.sub.2PO.sub.4, and Na.sub.2HPO.sub.4 to said propylene glycol, trimethoprim, and water solution at a temperature between about 50.degree. C. and about 55.degree. C. 4. The method of claim 1, wherein the catheter lock solution has a nominal viscosity between about 4.0-6.0 cps at 25.degree. C. and has a pH value between about 8 and about 9. 5. The method of claim 1, wherein the catheter lock solution has a nominal density set to match approximate human plasma density of about 1.02 g/ml. 6. A method to prepare a catheter locking solution, comprising the following steps in the following order: dissolving trimethoprim in propylene glycol at a temperature between about 50.degree. C. and about 55.degree. C. to form a solution of trimethoprim and propylene glycol; adding phosphate buffered saline to the solution of trimethoprim and propylene glycol at a temperature between about 50.degree. C. and about 55.degree. C. to form a solution of trimethoprim, propylene glycol, and phosphate buffered saline; adding EDTA Calcium Disodium Hydrate to the solution of trimethoprim, propylene glycol, and phosphate buffered saline at a temperature between about 50.degree. C. and about 55.degree. C. to form a solution of trimethoprim, propylene glycol, phosphate buffered saline, and EDTA Calcium Disodium Hydrate; adding glycerin to the solution of trimethoprim, propylene glycol, phosphate buffered saline, and EDTA Calcium Disodium Hydrate at a temperature between about 50.degree. C. and about 55.degree. C. to form a solution of trimethoprim, propylene glycol, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin; cooling the solution of trimethoprim, propylene glycol, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin to about room temperature; adding absolute ethanol at about room temperature to the solution of trimethoprim, propylene glycol, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin, at about room temperature, to form said catheter locking solution; wherein said phosphate buffered saline comprises an osmolality of about 287 milli-osmoles per kilogram; and wherein said catheter locking solution maintains shelf life stability, including no formation of precipitates, at temperatures between 0.degree. C. to about 42.degree. C. for at least three days. 7. The method of claim 6, wherein said phosphate buffered saline comprises no calcium salts or magnesium salts.

Details for Patent 10,335,518

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23